117 related articles for article (PubMed ID: 9738850)
1. Study on the in-vitro activity of LY333328 against gram-positive cocci.
Mezzatesta ML; Bonfiglio G; De Angelis L; Stefani S; Russo G
J Antimicrob Chemother; 1998 Aug; 42(2):266-8. PubMed ID: 9738850
[No Abstract] [Full Text] [Related]
2. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci.
Noviello S; Ianniello F; Esposito S
J Antimicrob Chemother; 2001 Aug; 48(2):283-6. PubMed ID: 11481302
[TBL] [Abstract][Full Text] [Related]
3. Glycopeptide-resistant Gemella haemolysans from blood.
Reed C; Efstratiou A; Morrison D; Woodford N
Lancet; 1993 Oct; 342(8876):927-8. PubMed ID: 8105186
[No Abstract] [Full Text] [Related]
4. An LY333328-dependent strain of Enterococcus faecalis isolated from a blood culture.
Wilson P; Koshy C; Minassian M
J Antimicrob Chemother; 1998 Sep; 42(3):406-7. PubMed ID: 9786489
[No Abstract] [Full Text] [Related]
5. Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model.
Rupp ME; Fey PD; Longo GM
J Antimicrob Chemother; 2001 May; 47(5):705-7. PubMed ID: 11328790
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of tigecycline against gram-positive cocci: a multicentre study in Greece.
Malli E; Spiliopoulou I; Kolonitsiou F; Neocleous Ch; Klapsa D; Pantelidi K; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou E; Petinaki E
J Antimicrob Chemother; 2008 Nov; 62(5):1158-60. PubMed ID: 18753190
[No Abstract] [Full Text] [Related]
7. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
8. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.
Frippiat F; Meunier F; Derue G
J Antimicrob Chemother; 2004 Dec; 54(6):1158; author reply 1159. PubMed ID: 15498877
[No Abstract] [Full Text] [Related]
9. Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study.
Boyanova L; Osmanliev D; Petrov D; Mitov I; Usunova I; Petrov S; Minchev TZ
Clin Microbiol Infect; 2000 Nov; 6(11):623-4. PubMed ID: 11168069
[No Abstract] [Full Text] [Related]
10. Daptomycin susceptibility of 833 strains of Gram-positive cocci from a university hospital in Japan (2009-2011).
Yoshizumi A; Ishii Y; Iwata M; Murakami H; Yumoto S; Yasui K; Maehara C; Fukuzawa S; Enokizono K; Tateda K
Diagn Microbiol Infect Dis; 2014 Oct; 80(2):151-3. PubMed ID: 25056827
[TBL] [Abstract][Full Text] [Related]
11. Problems with antimicrobial resistance in gram-positive cocci.
Moellering RC
Clin Infect Dis; 1998 May; 26(5):1177-8. PubMed ID: 9597248
[TBL] [Abstract][Full Text] [Related]
12. Introduction: treatment of Gram-positive infections.
Wise R
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii5-7. PubMed ID: 12797336
[No Abstract] [Full Text] [Related]
13. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.
Rolston KV; Dholakia N; Ho DH; LeBlanc B; Dvorak T; Streeter H
J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of bacteraemic isolates of gram-positive cocci to daptomycin and other antimicrobial agents.
Amsterdam D; Gorzynski EA; Beam TR; Rotstein C
J Antimicrob Chemother; 1994 May; 33(5):1060-4. PubMed ID: 8089056
[No Abstract] [Full Text] [Related]
16. Antibiotic therapeutic options for infections caused by drug-resistant Gram-positive cocci.
Banwan K; Senok AC; Rotimi VO
J Infect Public Health; 2009; 2(2):62-73. PubMed ID: 20701863
[TBL] [Abstract][Full Text] [Related]
17. [Introduction of Synercid].
Régnier B
Presse Med; 2001 Sep; 30(25 Pt 2):IV. PubMed ID: 11603272
[No Abstract] [Full Text] [Related]
18. New antibiotics against gram-positives: present and future indications.
Morata L; Mensa J; Soriano A
Curr Opin Pharmacol; 2015 Oct; 24():45-51. PubMed ID: 26232669
[TBL] [Abstract][Full Text] [Related]
19. Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity.
Anderegg TR; Biedenbach DJ; Jones RN;
J Clin Microbiol; 2003 Jun; 41(6):2795-6. PubMed ID: 12791936
[No Abstract] [Full Text] [Related]
20. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).
Castanheira M; Jones RN; Sader HS
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):235-9. PubMed ID: 18314293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
